SCHEMBL6435698

SCHEMBL6435698

CCCSc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)C[C@H]3C)c12

nearest known ligand 0.70

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 5/20 0.70
CYP2C19 P33261 6/20 0.65
CYP2C9 P11712 5/20 0.65
CYP3A4 P08684 3/20 0.57
GHSR Q92847 4/20 0.39
BTK Q06187 1/20 0.39
SLC6A7 Q99884 1/20 0.37
LIMK2 P53671 2/20 0.37
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PARP1 P09874 1/20 0.36
CFTR P13569 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C8 P10632 1/20 0.36
CYP2B6 P20813 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13554625 0.87 CYP2D6 (0.77) CYP2D6CYP2C19CYP2C9CYP3A4GHSR
SCHEMBL6431636 0.85 CYP2D6 (0.80) CYP2D6CYP2C19CYP2C9CYP3A4GHSR
SCHEMBL6435292 0.85 CYP2D6 (0.85) CYP2D6CYP2C19CYP2C9CYP3A4GHSR
SCHEMBL1763220 0.85 CYP2D6 (0.79) CYP2D6CYP2C19CYP2C9CYP3A4GHSR
SCHEMBL6432417 0.85 CYP2D6 (0.79) CYP2D6CYP2C19CYP2C9CYP3A4GHSR
SCHEMBL1763222 0.85 CYP2D6 (0.79) CYP2D6CYP2C19CYP2C9CYP3A4GHSR
SCHEMBL6431594 0.84 CYP2D6 (0.78) CYP2D6CYP2C19CYP2C9CYP3A4GHSR
SCHEMBL6431974 0.83 CYP2D6 (0.77) CYP2D6CYP2C19CYP2C9CYP3A4GHSR
SCHEMBL1763219 0.83 CYP2D6 (0.77) CYP2D6CYP2C19CYP2C9CYP3A4GHSR
SCHEMBL1763218 0.83 CYP2D6 (0.77) CYP2D6CYP2C19CYP2C9CYP3A4GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1257276-B1 ANTIVIRAL AZAINDOLE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-12-28 EP disclosed
US-6900323-B2 Antiviral azaindole derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2005-05-31 US disclosed
US-20040023982-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2004-02-05 US disclosed
US-6632819-B1 HIV and AIDS BRISTOL-MYERS SQUIBB COMPANY 2003-10-14 US disclosed
US-20030181463-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2003-09-25 US disclosed
US-6476034-B2 AIDS THERAPY BRISTOL-MYERS SQUIBB COMPANY 2002-11-05 US disclosed
US-20020119982-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2002-08-29 US disclosed
US-20020061892-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2002-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119982-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, AZI2 CYP2D6 1648/4885CYP2C19 3101/4885CYP2C9 3477/4885
US-20020061892-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, AZI2 CYP2D6 1648/4885CYP2C19 3101/4885CYP2C9 3477/4885
US-20040023982-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, EIF2AK2 CYP2D6 1508/4885CYP2C19 3009/4885CYP2C9 3466/4885
US-20030181463-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, AZI2 CYP2D6 1648/4885CYP2C19 3101/4885CYP2C9 3477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.